

ABSTRACT OF THE DISCLOSURE

The synthesis of novel diketopiperazines, their use in inhibiting cellular events such as those involving NFK- α , NFK- β and in the treatment of inflammation events, a combinatorial library of diverse diketopiperazines and process for their synthesis as a library and as individual compounds. In particular novel diketopiperazines are disclosed including their synthesis and use in cellular events such as activation of the transcription factor, nuclear factor, TNF- α , TNF- β and also apoptosis.